IMM-BCP-01 (the cocktail) contains three monoclonal antibodies that bind to nonoverlapping regions of the spike protein with picomolar affinity. The antibodies exhibit combinatorial effects in vitro against multiple SARS-CoV-2 variants, including those exhibiting both increased transmission in the U.S. and resistance to current antibody therapeutics and vaccines, according to Immunome.

The funds were awarded through the DOD's Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense in collaboration with the Defense Health Agency. The company received an initial award of $13.3 million from the DOD last year. The bump in funding will support expansion of the clinical study following feedback from the U.S. Food and Drug Administration.

Immunome SARS-CoV-2 antibody cocktail neutralizes variants
Immunome said that preclinical testing shows that its IMM-BCP-01 antibody cocktail neutralizes SARS-CoV-2 variants of concern.

ImmunoScape raises $14M for its deep immunomics platform
ImmunoScape has completed a financing round that raised $14 million to enlarge its Singapore-based team, further its expansion into the U.S., and...

Valo, ImmunoScape partner on pancoronavirus vaccine
Valo Therapeutics has completed a collaboration with ImmunoScape to identify immunogenic peptides for the development of a pancoronavirus vaccine.

Immunome discovers spike/nonspike SARS-CoV-2 antibodies
Immunome has isolated potent antibodies that are capable of neutralizing several SARS-CoV-2 variants, including the South African variant (B.1.351), in...